| Literature DB >> 32904764 |
Xiuru Yang1, Zhi Chen1, Wan Zhao1, Chunxi Liu1, Xiaoxiao Qian1, Ming Zhang2, Guoying Wei1, Eakalak Khan3, Yun Hau Ng4, Yong Sik Ok5.
Abstract
Antibiotics are widely present in the environment due to their extensive and long-term use in modern medicine. The presence and dispersal of these compounds in the environment lead to the dissemination of antibiotic residues, thereby seriously threatening human and ecosystem health. Thus, the effective management of antibiotic residues in water and the practical applications of the management methods are long-term matters of contention among academics. Particularly, photocatalysis has attracted extensive interest as it enables the treatment of antibiotic residues in an eco-friendly manner. Considerable progress has been achieved in the implementation of photocatalytic treatment of antibiotic residues in the past few years. Therefore, this review provides a comprehensive overview of the recent developments on this important topic. This review primarily focuses on the application of photocatalysis as a promising solution for the efficient decomposition of antibiotic residues in water. Particular emphasis was laid on improvement and modification strategies, such as augmented light harvesting, improved charge separation, and strengthened interface interaction, all of which enable the design of powerful photocatalysts to enhance the photocatalytic removal of antibiotics.Entities:
Keywords: Advanced materials; Clean water and sanitation; Green and sustainable remediation; High-performance photocatalyst; Reaction mechanisms for photodegradation
Year: 2020 PMID: 32904764 PMCID: PMC7457966 DOI: 10.1016/j.cej.2020.126806
Source DB: PubMed Journal: Chem Eng J ISSN: 1385-8947 Impact factor: 13.273
Methods for antibiotic degradation or removal in water.
| Adsorption processes | Anionic surfactant sodium dodecyl sulfate (SDS) | Amoxicillin | Contact time: 40 min | Low removal capacities; difficult separation; | |
| KOH-modified biochar | Norfloxacin | Temperature: 15–35 °C | |||
| Graphene oxide/cellulose nanofibril hybrid aerogel | Doxycycline | Temperature: 25 °C | |||
| Pyrogenic carbonaceous materials | Ciprofloxacin | Contact time: 72 h | |||
| Clean and dried | Ibuprofen | pH 2.5 or 5 | |||
| Manure-derived biochars | Lincomycin | pH 6 or 10 | |||
| Lanthanum modified diatomite | Tetracycline antibiotics | Contact time: 24 h | |||
| Adsorption processes | Grape stalk | Ofloxacin | pH 4, 7, and 9 | Low removal capacities; difficult separation; | |
| Cleaned and dried | Tetracycline | Temperature: 15–35 °C | |||
| Spent mushroom substrate | Sulfamethyldiazine | Temperature: 15 °C | |||
| Coagulation | Amino-acid-modified-chitosan flocculants | Norfloxacin | Temperature: 25 °C | Antibiotics cannot be completely removed and secondary pollution occurs readily | |
| Ozonation | Ozone | Amoxicillin | Neutral pH | Demands high equipment and energy costs | |
| Ozone/zero-valent iron | Flumequine | Contact time: 1h | |||
| Ozonation | Medium-high frequency ultrasound and ozone | Amoxicillin | Medium-high ultrasonic frequency waves: 575, 861, 1141 kHz | Demands high equipment and energy costs | |
| Ozone | Flumequine | Contact time: 6 min | |||
| Ozone | Ofloxacin | Temperature: 25 °C | |||
| Multistage ozone and biological treatment system | Amoxicillin | Temperature: 25 °C | Complex; high operating costs; continuous use is impractical | ||
| Chemical coagulation and microfiltration | Ibuprofen | Different doses of ZnO nanoparticles: 0.5, 0.7, 1.0, 1.3, 1.5, 1.7 g/L | |||
| Electric coagulation and photo-electro-Fenton process | Metronidazole | pH: 1, 3, 5, 7, 9 | |||
| Combined processes | A membrane bioreactor (MBR) integrated with solar Fenton oxidation | Sulfamethoxazole | H2O2: 20–100 mg/L | Complex; high operating costs; impracticability in continuous use | |
| Integrated adsorption-membrane filtration process | Norfloxacin | pH: 7 | |||
| Ultraviolet, chlorination, ozone disinfection | Antibiotic resistance genes | Chlorine concentrations: 2–32 mg/L | |||
| Adsorptive magnetic ion exchange resin | Sulfamethoxazole | Contact time: 30 min | |||
| Nanofiltration and chlorination | Sulfanilamide | Membrane effective area: 40.92 cm2 |
Fig. 1Number of search results of recent publications addressing the photocatalytic treatment of antibiotic residues using “photocatalytic” and “antibiotic treatment” as keywords (collected from the Web of Science Core Database: March 9, 2020).
Fig. 2Schematic representation of the semiconductor photocatalysis process [44]
Scheme 1Strategies for photocatalytic efficiency improvement.
Summary of previous studies using different strategies to improve photocatalytic degradation of antibiotics.
| Vacancies | BiOCl with abundant oxygen vacancies | 300-W Xe lamp | Tetracycline hydrochloride | Approximately 87% optimum within 2 h | |
| Vacancies | Oxygen vacancy-rich mesoporous ZrO2 | 300-W Xe lamp | Tetracycline hydrochloride | Approximately 80% optimum within 150 h | |
| Vacancies | BiOBr microspheres with oxygen vacancies | 10-W LED lamp (0.4 mW‧cm−2) | Tetracycline (TC) | Approximately 94% optimum within 90 min | |
| Vacancies | ZnWO4-x nanorods with oxygen vacancy | Hg lamp 300-W UV or 300-W Xe lamp (UV–Vis-NIR) | Tetracycline | Approximately 91% optimum within 90 min | |
| Vacancies | Bi2MoO6 with oxygen vacancy | 300-W Xe lamp | Ciprofloxacin | Approximately 55% optimum within 120 min | |
| Doping | Carbon-doped g-C3N4 | Sunlight | Tetracycline | Approximately 90% optimum within 90 min | |
| Doping | P-O co-doped g-C3N4 | 350-W Xe lamp (λ>420 nm) | Enrofloxacin10 mg/L | Approximately 90% within 80 min | |
| Doping | I and K co-doped g-C3N4 | 300-W Xe lamp (λ>420 nm) | Sulfamethoxazole | Approximately 99% optimum within 45 min | |
| Doping | Bi3+/g-C3N4 | 300-W Xe lamp (λ>420 nm) | Tetracycline | Approximately 94% optimum within 30 min | |
| Doping | Cr3+/SrTiO3 | 250-W Xe lamp (λ>420 nm) | Tetracycline | Approximately 70% optimum within 60 min | |
| Doping | Fe2+/Fe3+ immobilized on TiO2/fly-ash cenospheres | 150-W tungsten halogen lamp (λ>420 nm) | Ciprofloxacin | Approximately 80% optimum within 60 min | |
| Doping | Ce3+ doped Bi2O3 | 300-W lamp (visible light) | Tetracycline | Approximately 89% optimum within 180 min | |
| Doping | Ti3+/N co-doped TiO2/diatomite granule | 150-W Xenon lamp with a UV light filter | Tetracycline | 92% optimum within 150 min | |
| Quantum dots | CQDs modified Bi2MoO6 | 300-W Xe lamp (λ>400 nm) | Ciprofloxacin | 88% optimum within 2h | |
| Quantum dots | CQDs/BiOBr microspheres | Visible light irradiation | Ciprofloxacin | Approximately 65% optimum within 180 min | |
| Quantum dots | TiO2/C-dots | Average intensity sunlight irradiation (72 klx) | Levofloxacin | Approximately 99% optimum within 90 min | |
| Quantum dots | ZnSe QDs/g-C3N4 | 300-W Xe lamp (λ>400 nm) | Ceftriaxone sodium | Approximately 80% optimum within 120 min | |
| Quantum dots | Ag2O/TiO2 quantum dots | 400-W halogen bulb (similar to sunlight) | Levofloxacin | Approximately 81% optimum within 90 min | |
| Quantum dots | CQDs/BiOI | 300-W Xe lamp (λ>400 nm) | Tetracycline | Approximately 70% optimum within 120 min | |
| Quantum dots | CQDs/BiOBr | 300-W Xe lamp (λ>400 nm) | Tetracycline | Approximately 60% optimum within 120 min | |
| Quantum dots | MoS2 modified Zn-AgIn5S8 quantum dots | 250-W Xe lamp (λ>420 nm) | Tetracycline | Approximately 74% optimum within 4 min | |
| Quantum dots | 3D ZnS-RGO nanospheres | 300-W Hg vapor lamp | Norfloxacin | 92% optimum within 4h | |
| Phase junction | Porous core–shell homojunction | UV lamp (254 nm, 90 W, Philips) | Tetracycline hydrochloride | Approximately 81% within 300 min | |
| Facet junction | CaCu3Ti4O12 | 300-W Xe lamp | Tetracycline | Approximately 99% within 50 min | |
| Facet junction | AgBr tetradecahedrons with co-exposed (1 0 0) and (1 1 1) facets | 500-W halogen tungsten lamp (λ>420 nm) | Sulfadiazine | Approximately 90% optimum within 90 min | |
| Schottky heterojunction | Ag/Ag2MoO4 | 500-W Xe lamp (λ>420 nm) | Ciprofloxacin | Approximately 99% optimum within 60 min | |
| Schottky heterojunction | Ag/TiO2 (hollow nanosphere) | 125-W high-pressure Hg lamp, (λ>435.8 nm) | Metronidazole | Approximately 95% optimum within 120 min | |
| Schottky heterojunction | Bi/BiOBr (nano-flowers) | 300-W Xe lamp (λ>420 nm) | Tetracycline hydrochloride Ciprofloxacin and Doxycycline | Approximately 100% optimum within 30 min | |
| Schottky heterojunction | BiOCl-Ag (2D) | 200-W Xe arc lamp (λ<420 nm) | Sulfonamides | Approximately 80% optimum within 5h | |
| Schottky heterojunction | Ag/Bi3O4Cl | 250-W Xe lamp (λ>420 nm) | Tetracycline | Approximately 94% optimum within 120 min | |
| Schottky heterojunction | Ag/CCN | 300-W Xe lamp (λ>420 nm) | Tetracycline | 75% optimum within 15 min | |
| Schottky heterojunction | Pt/g-C3N4 | 300-W Xe lamp (λ>400 nm) | Tetracycline hydrochloride | Approximately 84% optimum within 40 min | |
| Schottky heterojunction | Bi (Spheres)/g-C3N4 | 300-W Xe lamp (λ>420 nm) | Amoxicillin | Approximately 5% optimum within 4 h | |
| Schottky heterojunction | W-doped BaTiO3 | Visible light irradiation | Tetracycline | Approximately 80% optimum within 3h | |
| Schottky heterojunction | Fe, Co, Ni, Fe-Co-, and Fe-Ni-doped ZnO | 300-W Xe lamp (λ=365 nm) | Oxytetracycline | Approximately 87% optimum within 2h | |
| Schottky heterojunction | Pt/Bi/TiO2 | 300-W halogen-tungsten lamp (λ>420 nm) | Amoxicillin | Approximately 87% optimum within 2h | |
| Schottky heterojunction | Au/Pt/g-C3N4 | 500-W Xe lamp (λ>400 nm) | Tetracycline hydrochloride | Approximately 90% optimum within 3h | |
| Schottky heterojunction | 0D Bi nanodots/2D Bi3NbO7 nanosheets | 300-W Xe lamp (λ>400 nm) | Ciprofloxacin | Approximately 86% optimum within 120 min | |
| Type Ⅱ heterojunction | AgI/BiVO4 | 300-W Xe lamp (λ>420 nm) | Tetracycline (TC) | Approximately 94% optimum within 1h | |
| Type Ⅱ heterojunction | 3D porous CdS/TiO2 | 300-W Xe lamp (λ>420 nm) | Tetracycline and oxytetracycline (OTC) | Approximately TC: 67% and OTC: 81% optimums within 50 min | |
| Type Ⅱ heterojunction | MgFe2O4/MoS2 | Radiation intensity: 47 mW/cm2 | Tetracycline | Approximately 92% optimum within 120 min | |
| Type Ⅱ heterojunction | ZnWO4-CdS | 300-W Xe lamp (λ>420 nm) | Ciprofloxacin | Approximately 90% optimum within 1h | |
| Type Ⅱ heterojunction | ZnO@ZnS nanorod | 500-W Xe lamp | Tetracycline | Approximately 80% within 140 min | |
| Type Ⅱ heterojunction | MoS2/PbBiO2I | 300-W Xe lamp (λ>400 nm) | Ciprofloxacin | Approximately 80% optimum within 6h | |
| Type Ⅱ heterojunction | Bi2SiO5/Bi12SiO20 | 100-W high-pressure Hg lamp | Tetracycline | Approximately 79% optimum within 30 min | |
| Type Ⅱ heterojunction | SrTiO3/Fe2O3 | 250-W Xe lamp (λ>420 nm) | Tetracycline | Approximately 83% optimum within 140 min | |
| Type Ⅱ heterojunction | p-C3N4/f-BiOBr | 250-W Xe lamp (λ>400 nm) | Tetracycline | Approximately 94% optimum within 300 min | |
| Type Ⅱ heterojunction | Bi2O7Sn2-Bi7O9I3 | Halogen lamp as simulated solar light | Tetracycline | 80% optimum within 90 min | |
| Type Ⅱ heterojunction | NiFe2O4/Bi2O3 | 150-W xenon lamp (λ>420 nm) | Tetracycline | Approximately 91% optimum within 90 min | |
| Type Ⅱ heterojunction | BiVO4/rGO | 250-W Xe lamp (λ>420 nm) | Tetracycline | 99% optimum within 90 min | |
| Type Ⅱ heterojunction | SrTiO3 nanocube coated CdS microsphere | 250-W Xe lamp (λ>400 nm) | Ciprofloxacin | Approximately 94% optimum within 120 min | |
| Type Ⅱ heterojunction | g-C3N4/BiPO4 | 250-W high-pressure Hg lamp | Ciprofloxacin | Approximately 97% optimum within 120 min | |
| Type Ⅱ heterojunction | g-C3N4/Ag3PO4 | 300-W Xe lamp (λ>400 nm) | Ciprofloxacin | Approximately 67% optimum within 15 min | |
| Type Ⅱ heterojunction | In2S3/NaTaO3 | 300-W Xe lamp | Tetracycline hydrochloride | Approximately 80% optimum within 180 min | |
| Type Ⅱ heterojunction | Polyaniline/Bi4O5Br2 | Visible light | Ciprofloxacin | CIP: 99% optimum within 50 min, TC: approximately 86% optimum within 240 min | |
| Type Ⅱ heterojunction | CdS nanoparticles/porous carbon polyhedrons | 300-W Xe lamp (λ>420 nm) | Cephalexin | Approximately 90% optimum within 90 min | |
| Type Ⅱ heterojunction | Microsphere-like In2S3/InVO4 | 300-W Xe lamp (λ>420 nm) | Tetracycline | Approximately 71% optimum within 60 min. | |
| Type Ⅱ heterojunction | g-C3N4/Bi4O5Br2 | 300-W Xe arc lamp | Ciprofloxacin | Approximately 67% optimum within 150 min | |
| Type Ⅱ heterojunction | Bi2WO6/g-C3N4 | 300-W Xe lamp UV light | Ceftriaxone sodium | Approximately 94% optimum within 120 min | |
| Type Ⅱ heterojunction | Flower-root shaped Bi2O3/Bi2MoO6 | 500-W Xe lamp (λ>420 nm) | Tetracycline | Approximately 70% optimum within 190 min | |
| Type Ⅱ heterojunction | Covalent triazine framework modified BiOBr nanoflake | 500-W Xe lamp | Tetracycline | Approximately TC: 90% and CIP: 60% optimums within 50 min | |
| Type Ⅱ heterojunction | mpg-C3N4 and Bi2WO6 nest-like structure | 300-W Xe lamp (λ>420 nm) | Tetracycline hydrochloride | Approximately 75% optimum within 120 min | |
| Type Ⅱ heterojunction | TiO2 nanoparticle/SnNb2O6 nanosheet heterojunctions | 500-W tungsten lamp | Tetracycline hydrochloride | Approximately 76% optimum within 240 min | |
| Type Ⅱ heterojunction | Bi4Ti3O12/BiOCl (2D/0D) composite | 300-W Xe lamp | Tetracycline hydrochloride | Approximately 84% optimum within 150 min | |
| Type Ⅱ heterojunction | 2D-2D g-C3N4/Bi4O5Br2 | 300-W Xe lamp (λ>400 nm) | Ciprofloxacin | Approximately 50% optimum within 30 min | |
| Type Ⅱ heterojunction | 2D/2D Bi4Ti3O12/I-BiOCl | 350-W Xe arc lamp (λ>420 nm) | Ciprofloxacin | Approximately 90% optimum within 120 min | |
| Type Ⅱ heterojunction | Carbon-doped carbon nitride/Bi12O17Cl2 | 300-W Xe lamp (λ>420 nm) | Tetracycline | 94% optimum within 60 min | |
| Type Ⅱ heterojunction | CuBi2O4/CuO | Visible light | Metronidazole | 36% optimum within 120 min | |
| p-n heterojunction | p-n type BiOCl/titanium phosphate nanoplates | 300-W Xe lamp | Ciprofloxacin | Approximately 100% within 5 min | |
| p-n heterojunction | p-n type CoO/g-C3N4 | 300-W Xe lamp (λ>420 nm) | Tetracycline | Approximately 90% within 60 min | |
| p-n heterojunction | p-n type Cu2O/SrTiO3 | 150-W Xe lamp (λ>420 nm) | Tetracycline | Approximately 79% within 100 min | |
| p-n heterojunction | p-n type flower-like BiOCl/BiOCOOH p-n | 300-W Xe lamp simulated sunlight | Tetracycline | Approximately 80% within 60 min | |
| p-n heterojunction | p-n type Ag2O/g-C3N4 | 500-W Xe lamp (λ>400 nm) | Tetracycline hydrochloride | Approximately 94% within 3h | |
| p-n heterojunction | p-n type Co3O4-C3N4 | Sunlight | Tetracycline | Approximately 97% within 180 min | |
| p-n heterojunction | p-n type 3D flower-like BiOBr/Bi2SiO5 | 300-W Xe lamp (λ>420 nm) | Tetracycline | 91% within 120 min | |
| p-n heterojunction | n-p type SnO2 nanoparticles/BiOI | 300-W Xe lamp (λ>420 nm) | Oxytetracycline hydrochloride | Approximately 94% optimum within 90 min | |
| p-n heterojunction | p-n type N-graphene QDs-BiOI/MnNb2O6 | 250-W Xe lamp (λ>420 nm) | Tetracycline | Approximately 87% optimum within 60 min | |
| p-n heterojunction | p-n type Fe3O4 quantum dots modified BiOCl/BiVO4 | 300-W Xe lamp (λ>420 nm) | Sulfamethoxazole (SMX, 5 mg/L), TC (20 mg/L), norfloxacin (NOR, 10 mg/L), and CIP (10 mg/L) | SMX: 91% within 90 min, TC: 87% within 30 min, NOR: 89% within 60 min, CIP: 87% within 90 min | |
| Double heterojunction | CDs/MoS2/TiO2 nanobelt | 250-W Xe lamp (λ>420 nm) | Tetracycline | Approximately 82% within 3h | |
| Double heterojunction | (g-C3N4)-ZnO/halloysite nanotubes (HNTs) | 350-W Xe arc lamp | Tetracycline | Approximately 87% optimum within 60 min | |
| Double heterojunction | Ultrathin g-C3N4 nanosheets coupled with amorphous Cu doped FeOOH nanoclusters as 2D/0D heterogeneous catalysts | 500-W Xe lamp (λ>420 nm) | Tetracycline | Approximately 90% within 40 min | |
| Double heterojunction | 2D/2D/2D CoAl-LDH/g-C3N4/RGO ternary heterojunction | 300-W halogen lamp visible-light irradiation | Tetracycline | Approximately 100% optimum within 60 min | |
| Double heterojunction | Ag-AgVO3/g-C3N4 | 300-W Xe lamp (λ>410 nm) | Tetracycline | Approximately 84% optimum within 120 min | |
| Double heterojunction | ZnFe2O4/Ag/Ag3VO4 | Visible-light irradiation | Tetracycline | Approximately 60% within 10 min | |
| Double heterojunction | NiS and MoS2 nanosheet co-modified g-C3N4 ternary heterostructure | 250-W metal halide lamp (λ>400 nm) | Tetracycline | Approximately CIP: 71% and TC: 96% optimums, within 120 min | |
| Double heterojunction | AgCl/Ag3PO4/ g-C3N4 | Visible-light irradiation (λ>400 nm) | Sulfamethoxazole | Approximately 100% optimum within 90 min | |
| Double heterojunction | 3D Ag3PO4/TiO2@MoS2 | 800-W Xe arc lamp | OTC 5 mg/L | Approximately OTC: 75%, ENR: 92% within 10 min | |
| Double heterojunction | Bi2O3/BiOCl supported on graphene sand (BO/BOC/GSC) composite (BO/BOC/CT) | Solar light intensity (35 × 103 ± 1000 lx) | Oxytetracycline | BO/BOC/GSC: approximately 90% for AMP and OTC | |
| Double heterojunction | Core-shell structured Fe3O4@SiO2@CdS | 1000-W tungsten-halide lamp (Philips) (λ>420 nm) | Tetracycline | Approximately 80% optimum within 21 min | |
| Double heterojunction | RGO-CdS/ZnS | 300-W Xe lamp (λ>420 nm) | Tetracycline | Approximately 90% optimum in 60 min | |
| Double heterojunction | TiO2/Bi2WO6/carbon fibers | 300-W Xe lamp (λ>400 nm) | Tetracycline hydrochloride | Approximately 95% optimum within 60 min | |
| Z-scheme heterojunction | Z-scheme beta-Bi2O3@g-C3N4 core/shell nanocomposite | 250-W Xe lamp (λ>420 nm) | Tetracycline | Approximately 80% optimum within 50 min | |
| Z-scheme heterojunction | Z-scheme WO3-g-C3N4 | 300-W Xe arc lamp (1.5 AM solar simulator) | Sulfamethoxazole | Approximately 92% optimum within 4h | |
| Z-scheme heterojunction | Z-scheme AgI nanoparticle-sensitized Bi5O7I microspheres | 300-W Xe lamp | TC (20 mg/L), DTC (10 mg/L), OTC (10 mg/L), or CIP (10 mg/L) | Approximately TC: 95%, DTC: 90%, OTC: 80% and CIP: 90% optimums within 40 min | |
| Z-scheme heterojunction | Z-scheme CdTe/TiO2 | 400-W halogen lamp (λ>400 nm) | Tetracycline hydrochloride | Approximately 78% optimum within 30 min | |
| Z-scheme heterojunction | Type II AgI/CuBi2O4 | 300-W Xe lamp | Tetracycline | Approximately Type II catalyst: 80% and Z-scheme catalyst: 90% optimums within 30 min | |
| Z-scheme heterojunction | Z-scheme mesoporous Sn3O4 nanoclusters/g-C3N4 nanosheets | 500-W Xe lamp | Tetracycline hydrochloride | Approximately 72% optimum within 120 min | |
| Z-scheme heterojunction | Z-scheme Bi3TaO7 QDs/g-C3N4 nanosheets (NSs) | LED lamp | CIP and CPX | Approximately CIP: 91%, CPX: 77% CPX within 120 min | |
| Z-scheme heterojunction | Z-scheme WO3 nanosheet/K+Ca2Nb3O10− ultrathin nanosheet | 250-W xenon lamp as simulated sunlight (no filters). | Tetracycline hydrochloride | Approximately 86% optimum within 120 min | |
| Z-scheme heterojunction | Z-scheme AgI/BiOBr | 300-W Xe lamp (λ>420 nm) | Ciprofloxacin | Approximately 91% optimum within 1h | |
| Z-scheme heterojunction | Z-scheme Ag3PO4/g-C3N4 | 300-W Xe lamp (λ>400 nm) | Sulfamethoxazole | Approximately 99% optimum within 90 min | |
| Z-scheme heterojunction | Z-scheme CdS-Au-BiVO4 (0 1 0) | 300-W Xe lamp (λ>420 nm) | Tetracycline | 91% optimum within 90 min | |
| Z-scheme heterojunction | Z-scheme BiVO4/Ag/Cu2O | 300-W Xe lamp (λ>420 nm) | Tetracycline | Approximately 91% optimum within 90 min | |
| Z-scheme heterojunction | Z-scheme ZnFe2O4/Ag/PEDOT | 250-W xenon lamp (1.8×105 lx) | Tetracycline | Approximately 72% optimum within 120 min | |
| Z-scheme heterojunction | Organic-inorganic Z-scheme PANI/Ag/Ag2MoO4 | 40-W UV tube (Phillips) | Ciprofloxacin | Approximately 100% optimum within 40 min | |
| Z-scheme heterojunction | Z-scheme (0 0 1) BiOCl-Au-CdS | 300-W Xe lamp (AM 1.5) | Sulfadiazine | Approximately 91% optimum within 4h | |
| Z-scheme heterojunction | Z-scheme iodine vacancy-rich BiOI/Ag@AgI | 300-W Xe lamp (λ>420 nm) | Tetracycline | Approximately 86% optimum within 60 min | |
| Z-scheme heterojunction | Z-scheme Ag2CO3/Ag/WO3 | 300-W Xe lamp (λ>420 nm) | CIP and TC | Approximately CIP: 84% and TC: 81% optimums within 90 min | |
| Z-scheme heterojunction | Z-scheme AgI/Ag/Bi3TaO7 | 300-W Xe lamp (visible light) | Sulfamethoxazole | Approximately 98% optimum within 100 min | |
| Z-scheme heterojunction | Z-scheme MIL-53(Fe)/Ag/g-C3N4 | Visible light | Clioquinol | 95% optimum within 100 min | |
| Z-scheme heterojunction | Z-scheme CeVO4/3D RGO aerogel/BiVO4 | 500-W Xe lamp | Tetracycline | Approximately 100% optimum within 60 min | |
| Z-scheme heterojunction | TCPP/rGO/Bi2WO6 | 300-W Xe lamp (λ>420 nm) | Tetracycline | Approximately 84% optimum within 60 min | |
| Z-scheme heterojunction | Z-scheme Ag3PO4/Bi2S3/Bi2O3 | 300-W Xe lamp | Sulfamethazine (SAZ) and cloxacillin (CLX) | Approximately SAZ: 99% and CLX: 90% optimums within 90 min | |
| Z-scheme heterojunction | RGO-Ag2O/TiO2 | 350-W Hg lamp (λless than356 nm), 300-W Xe arc lamp (visible light), 300-W infrared lamp, and 156-W APOLLO solar simulator | Tetracycline | 100% and approximately 100% optimums within 60 min, approximately 90% optimums within 120 min | |
| Z-scheme heterojunction | Z-scheme g-C3N4/Ag2CO3/graphene oxide | 300-W Xe lamp | Tetracycline | Approximately 82% optimum within 60 min | |
| Z-scheme heterojunction | Z-scheme nitrogen-doped graphene QDs-BiVO4/g-C3N4 | 250-W Xe lamp | Tetracycline | Approximately 91% optimum within 30 min | |
| Z-scheme heterojunction | Z-scheme graphitic carbon nitride (CN) and reduced graphene oxide (rGO) with AP | Both intense sunlight and weak indoor light irradiation | Norfloxacin | Approximately 100% optimum within 30 min and 85% optimum within 2h | |
| Z-scheme heterojunction | Z-scheme WO3/Fe3O4/g-C3N4 | 300-W Xe lamp | Tetracycline | 89% optimum within 120 min | |
| Z-scheme heterojunction | Z-scheme nitrogen-doped hollow mesoporous carbon spheres (N-HMCs) modified g-C3N4/Bi2O3 | 300-W Xe lamp | Tetracycline hydrochloride (TCH) and ciprofloxacin hydrochloride (CFH) | Approximately 90% and 80% optimum within 60 min | |
| Exposing active facets | Bi2O2(OH)(NO3) nanosheets with (0 0 1) active exposing facets | UV light irradiation | Tetracycline hydrochloride | Approximately 98% optimum within 25 min | |
| Exposing active facets | Ultrathin Bi2O2(OH)xCl2-x solid solution with exposed (0 0 1) facets | Visible light | Ciprofloxacin | Approximately 90% optimum within 150 min | |
| Exposing active facets | Nanosheet BiVO4 with oxygen vacancies and exposed (0 0 1) facets | 500-W Xe lamp without optical filters to simulate the sunlight | Oxytetracycline | Approximately 96% optimum within 2h | |
| Exposing active facets | Various well-defined Bi2WO6 crystals | 300-W Xe lamp | Ciprofloxacin | Approximately 70% optimum within 5h | |
| Exposing active facets | Doped BiOCl nanoplates | 300-W Xe lamp (λ>420 nm) | Tetracycline hydrochloride | Approximately 90% optimum within 100 min | |
| Exposing active facets | (0 0 1) Ag@NC-TiO2 square nanosheets | 350-W Xe arc lamp (λ>420 nm) | Ciprofloxacin | Approximately 97% optimum within 150 min | |
| Exposing active facets | TiO2@g-C3N4 core–shell quantum | Xe lamp irradiation. | Tetracycline | Approximately 100% optimum within less than 10 min | |
| Porous materials | Intercalate structure g-C3N4@ATP | 300-W Xe lamp (λ>420 nm) | Tetracycline | Approximately 90% optimum within 2h | |
| Porous materials | 3D hierarchical mesoporous BiOI | 1000-W tungsten halogen lamp | Tetracycline hydrochloride | Approximately 100% optimum within 37.5 or 101.5 min | |
| Porous materials | BiOI hollow microspheres | 300-W Xe lamp (λ>400 nm) | Tetracycline | 80% optimum within 120 min | |
| Porous materials | Ultra-thin Bi2MoO6 nanosheets | Sunlight | Ofloxacin | Approximately 71% optimum within 90 min | |
| Tailoring morphology | Rod-like SrV2O6 | 500-W tungsten lamp (λ>400 nm) | Metronidazole | 98% optimum within 60 min | |
| Tailoring morphology | TiO2 nanobelts | Simulative solar light | Amikacin | Approximately 70% optimum within 150 min | |
| Tailoring morphology | ZnO Nanotubes | 300-W Xe lamp (AM1.5 filter (1000 Wm−2)) | Ciprofloxacin | Approximately 12% optimum within 2h | |
| Tailoring morphology | Bi5FeTi3O15 | 300-W Xe lamp | Tetracycline hydrochloride | Approximately 99% optimum within 1h | |
| Tailoring morphology | Navel-like Bi2WO6 hierarchical microspheres | UV light irradiation (λ=365 nm) | Norfloxacin | Approximately 67% optimum within 8h | |
| Tailoring morphology | spearhead-like g-C3N4 | Xe lamp | Tetracycline | Approximately 70% optimum within 180 min | |
| 3D aerogel | g-C3N4@CA/B-PET | Artificial solar light | Sulfaquinoxaline sodium | Approximately 100% optimum within 60 min | |
| 3D aerogel | BiVO4/3D RGO aerogel/CeVO4 | 500-W Xe lamp | Tetracycline | Approximately 90% optimum within 120 min | |
| 3D aerogel | 3D MoS2 nanosheets/graphene aerogel | 300-W Xe lamp | Tetracycline hydrochloride | Approximately 10% optimum within 75 min |
Fig. 3Schematic of the OV-induced photocatalytic process on ZnWO4-x[54]
Fig. 4(a) UV–vis diffuse reflectance spectra of a) 1) raw TiO2 (5 0 0), and N-TiO2 (T) samples prepared at 2) 450, 3) 500, 4) 550, 5) 600, 6) 700 and 7) 800 °C [247], (b) diffuse reflection spectra (DRS) curves of undoped and doped TDHG [63], Inset: Photographs of TDHG, N-TDHG, b -TDHG and b/N-TDHG photocatalysts.
Fig. 5(a) Light absorption curves [252] and (b) photocatalytic mechanisms of CQD/TNT photocatalyst [253]
Fig. 6Mott-Schottky curves on (a) CN and (b) PN-2; (c and d) schematic of carrier migration at the p-n homojunction [201]
Fig. 7(a) Photodegradation of TC by the as-synthesized plasmonic Ag/Bi3O4Cl under visible irradiation, (b) possible photocatalytic mechanisms on the Ag/Bi3O4Cl samples [79], (c) photocatalytic kinetics of prepared g-C3N4, Pt/g-C3N4, Au/g-C3N4, and Au/Pt/g-C3N4 nanocomposites [86] (d) schematic of the g-C3N4 photoinduced charge transport [284]
Fig. 8Preparation process for g-C3N4/Bi4O5Br2 nanocomposites [114]
Fig. 9(a) Roadmap of Z-scheme photocatalytic system evolution [293]; (b) suggested photoinduced charge transport on g-C3N4(60)/TNTAs [296]
Fig. 10Photocatalytic degradation mechanisms of CR and TC by a ternary LDH/CN/RGO heterostructure [130]
Fig. 11Synthesis of BiVO4/RGO/CeVO4 heterostructures [159]